ABVC BioPharma Return on Equity

ABVC BioPharma (ABVC) currently reports a ROE of -6.01%. That is below the Industrials sector average of 22.38%. Use the charts on this page to explore ABVC BioPharma's ROE history and peer comparisons.

ABVC BioPharma's ROE of -6.01% is lower than the Industrials sector average of 22.38%. That is roughly 126.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ABVC BioPharma's current -6.01% should be judged against Industrials norms (sector average: 22.38%) and against ABVC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -6.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 22.38%. From there, open related valuation or income-statement pages for ABVC BioPharma, and consider following ABVC for alerts when major investors trade the stock.

ABVC BioPharma is classified in the Industrials sector. On ROE, it currently shows -6.01% versus a sector average near 22.38%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing ABVC with unrelated industries.